Indoco Remedies shareholding pattern

Who owns itSep 2026 quarter

Promoters58.92%+0.06 pts
Foreign investors (FII)1.64%+0.37 pts
Domestic institutions (DII)16.64%−1.04 pts
of which mutual funds16.44%−0.72 pts
Public22.66%
Others0.14%

Per cent of all shares; change on the Jun 2026 quarter, in percentage points. As filed with the exchanges.

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

INDOCO₹213.75

Indoco Remedies Limited

· Pharma & Health
₹ CrorePeersSAIPARENTPANACEABIOHIKALWINDLASHESTERBIODCALSYNCOMFSOLARAMcap ₹1,973 Cr
Holding % of Total Shares
12 Months Ending
Q1 FY25
30/06/2024
Q2 FY25
30/09/2024
Q3 FY25
31/12/2024
Q4 FY25
31/03/2025
Q1 FY26
30/06/2025
Q2 FY26
30/09/2025
Q3 FY26
31/12/2025
Q4 FY26
31/03/2026
Q1 FY27
30/06/2026
Q2 FY27
30/09/2026
Promoter & Group58.7558.7558.8058.9058.9058.9058.9058.8658.8658.92
FII / FPI1.471.701.251.241.221.251.100.941.271.64
DII18.6718.2418.9018.7518.9618.1618.1518.1517.6816.64
Mutual Funds17.0416.7418.2118.5218.5517.5817.5517.5417.1616.44
Latest: 2026-09-30 · 21 quarters of history · click a row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.